Holen Sie sich die Stockscreener-App
292.67
0.07%
-0.20
Handel nachbörslich:
292.67
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$292.87
Offen:
$291.66
24-Stunden-Volumen:
788.59K
Relative Volume:
0.54
Marktkapitalisierung:
$56.73B
Einnahmen:
$310.23B
Nettoeinkommen (Verlust:
$1.69B
KGV:
33.95
EPS:
8.62
Netto-Cashflow:
$3.58B
1W Leistung:
-1.48%
1M Leistung:
-0.34%
6M Leistung:
+19.42%
1J Leistung:
+30.89%
1-Tages-Spanne:
$289.47
$294.63
1-Wochen-Bereich:
$289.47
$298.44
52-Wochen-Spanne:
$218.65
$309.35
Cencora Inc Stock (COR) Company Profile
Firmenname
Cencora Inc
Sektor
Branche
Telefon
610-727-7000
Adresse
1 WEST FIRST AVENUE, CONSHOHOCKEN
Vergleichen Sie COR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
COR
Cencora Inc
|
292.67 | 57.58B | 310.23B | 1.69B | 3.58B | 8.62 |
|
MCK
Mckesson Corporation
|
711.21 | 89.38B | 359.05B | 3.30B | 5.23B | 25.83 |
|
CAH
Cardinal Health Inc
|
158.58 | 38.59B | 222.29B | 1.56B | 2.44B | 6.41 |
|
HSIC
Henry Schein Inc
|
69.07 | 8.84B | 12.50B | 314.00M | 421.00M | 2.44 |
|
AHG
Akso Health Group Adr
|
2.025 | 658.06M | 2.22M | -5.63M | -1.68M | -0.24 |
Cencora Inc Stock (COR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-12-04 | Fortgesetzt | Mizuho | Outperform |
| 2024-09-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2024-01-03 | Eingeleitet | Barclays | Overweight |
| 2023-12-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-03-31 | Eingeleitet | Citigroup | Buy |
| 2023-01-31 | Fortgesetzt | Evercore ISI | Outperform |
| 2022-10-11 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-08-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-11 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-06-07 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-05-26 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-04-12 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-12 | Fortgesetzt | Evercore ISI | In-line |
| 2021-02-04 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-02-02 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-01-06 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-01-06 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-10 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2020-12-03 | Eingeleitet | Mizuho | Neutral |
| 2020-08-06 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-07-15 | Eingeleitet | Barclays | Underweight |
| 2020-06-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-23 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-04-16 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-04-13 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-04-01 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-03-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-11 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2020-02-07 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-09-12 | Eingeleitet | Deutsche Bank | Hold |
| 2019-07-10 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-04-11 | Eingeleitet | Guggenheim | Buy |
| 2019-04-10 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2019-04-10 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-02-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-01-17 | Eingeleitet | UBS | Buy |
| 2018-12-10 | Herabstufung | Jefferies | Buy → Hold |
| 2018-10-26 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-09-20 | Eingeleitet | Berenberg | Buy |
| 2018-07-17 | Fortgesetzt | Stifel | Hold |
| 2018-04-09 | Eingeleitet | MoffettNathanson | Buy |
| 2018-03-12 | Hochstufung | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-03-12 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2017-09-25 | Eingeleitet | JP Morgan | Neutral |
| 2017-09-22 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Cencora Inc Aktie (COR) Neueste Nachrichten
What analysts say about Cencora Inc. stockSkyrocketing investment returns - Autocar Professional
Is Cencora Inc. a good long term investmentOutperformance with explosive growth - Autocar Professional
Cencora Inc. Stock Analysis and ForecastSuperior returns - jammulinksnews.com
Published on: 2025-07-19 01:21:27 - beatles.ru
What drives Cencora Inc. stock priceRecord-breaking gains - Jammu Links News
Cencora Slumps to 447th in Market Rankings as Trading Volume Drops 40.48 Percent - AInvest
Here's Why You Should Add Cencora Stock to Your Portfolio Now - MSN
Cencora Surges to 261st in Daily Rankings with 3.90 Billion Trading Volume - AInvest
Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora - BioSpace
Cencora (COR) Partners With Citius Oncology For Immunotherapy Distribution Expansion - simplywall.st
Citius Oncology Expands Lymphir Distribution With Cencora - MarketScreener
Citius Oncology expands distribution network for LYMPHIR with Cencora - Investing.com Australia
Citius stock gains on Cencora distribution deal (CTXR:NASDAQ) - Seeking Alpha
Citius Oncology expands distribution network for LYMPHIR with Cencora By Investing.com - Investing.com Nigeria
Lobbying Update: $20,000 of CENCORA INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) lobbying was just disclosed - Quiver Quantitative
Here's What to Expect From Cencora's Next Earnings Report - MSN
Cencora, Inc. (COR): If It Was Down, I’d Say “Double Down And Buy,” Says Jim Cramer - Insider Monkey
Will Cencora (COR) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Cencora to Announce Q3 2025 Results on August 6 with Live Webcast and Conference Call - MSN
Fund Update: FERGUSON WELLMAN CAPITAL MANAGEMENT, INC added 79,430 shares of CENCORA ($COR) to their portfolio - Quiver Quantitative
Here's What To Expect From Cencora's Next Earnings Report - Barchart.com
Cencora Enhances Receivables Purchase Agreement for Liquidity - The Globe and Mail
Cencora Trading Volume Drops 40.8% to $385 Million Ranking 278th in Market - AInvest
Mizuho maintains Cencora stock rating on strong Walgreens data - Investing.com
Cencora's Insider Exodus: Risk or Opportunity? - AInvest
Cencora Executive VP & Chief Human Resources Officer Silvana Battaglia Sells 27% Of Holding - simplywall.st
Cencora, Inc.: Insider Selling and Overvaluation—Is This a Red Flag or Opportunity? - AInvest
Insider Sell: Silvana Battaglia Sells Shares of Cencora Inc (COR) - GuruFocus
Three fund managers share picks for tariff-resistant U.S. stocks - The Globe and Mail
$100 Invested In Cencora 5 Years Ago Would Be Worth This Much Today - Benzinga
Cencora Welcomes Lori J. Ryerkerk to Board of Directors - MSN
Cencora Inc. stock outperforms competitors on strong trading day - MarketWatch
Is Cencora Stock Outperforming The Dow? - Barchart.com
Is Cencora Stock Outperforming the Dow? - The Globe and Mail
Cencora, Inc. (COR) Enhances Financial Flexibility with Amended Credit Agreements - GuruFocus
Cencora Enhances Financial Flexibility with Credit Amendments - TipRanks
Cencora IncIncreases Revolving Credit Facility To $4.5 Billion - MarketScreener
Cardinal Health, Cencora upgraded at Wells Fargo on industry outlook - MSN
Cravath Advises on €1B Cencora Notes Offering - Lawyer Monthly
Mizuho Adjusts Price Target on Cencora to $316 From $315, Maintains Outperform Rating - marketscreener.com
Cencora (NYSE:COR) Upgraded by Wells Fargo & Company to “Overweight” Rating - Defense World
Wells Fargo Upgrades Cencora (COR) Stock to Overweight, Lifts PT - MSN
Cencora (COR) Receives Upgrade as Analysts Set New Price Target - GuruFocus
Wells Fargo Upgrades Cencora (COR) - Nasdaq
Wells Fargo upgrades Cencora stock rating, raises price target to $337 - Investing.com Nigeria
Finanzdaten der Cencora Inc-Aktie (COR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.61%
0.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):